Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

HuMax-CD20 in Chronic Lymphocytic Leukemia

This study has been completed.
Sponsor:
Information provided by:
Genmab
ClinicalTrials.gov Identifier:
NCT00093314
First received: October 6, 2004
Last updated: January 5, 2007
Last verified: January 2007